Cassava is available year round. It’s quite hard to peel, so it’s easiest to buy it ready prepared and frozen. If you do see it fresh, look for a clear outer skin and white flesh. Cassava ...

It's easy to get so engrossed in creating ridiculously funny emojis that you might forget to send them. This guide explains what Emoji Kitchen is and how to use it to spice up your conversations.

An emoji that speaks for the tired masses is coming to little screens soon. One of eight new emoji set to debut late this year and into the next, an exhausted face with bags beneath its eyes is ...

Finally, an emoji to represent us all is coming soon: An exhausted face with bags under its eyes. It’s one of eight new emojis that will appear on smartphones and computers next year ...

Text messages and chats online can include a combination of words, pictures and emoji to convey a message. Words and pictures can be easily understood, but deciphering emoji might feel like ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

In our series of letters from African journalists, Ghanaian Elizabeth Ohene considers the call of Uganda's President Yoweri Museveni for people to eat the humble cassava as the price of wheat ...

Cassava faces a cash burn of $80-$90 million in the second half of 2024, which will significantly reduce its current cash runway. Due to data integrity issues and unproven efficacy, I maintain a ...

The research behind Cassava Sciences’ Alzheimer’s drug candidate, simufilam, and the idea of targeting a brain protein called filamin, is based on a series of papers from a group at CUNY and ...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 ...

Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for ...